Masimo Corporation (NASDAQ: MASI) and Tactile Systems Technology (NASDAQ:TCMD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.
Valuation & Earnings
This table compares Masimo Corporation and Tactile Systems Technology’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Masimo Corporation||$730.06 million||6.10||$182.11 million||$6.14||13.97|
|Tactile Systems Technology||$97.23 million||6.12||$3.09 million||$0.25||135.36|
This table compares Masimo Corporation and Tactile Systems Technology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tactile Systems Technology||4.97%||3.05%||2.54%|
This is a breakdown of current recommendations and price targets for Masimo Corporation and Tactile Systems Technology, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tactile Systems Technology||0||0||4||0||3.00|
Masimo Corporation currently has a consensus target price of $97.00, indicating a potential upside of 13.08%. Tactile Systems Technology has a consensus target price of $33.00, indicating a potential downside of 2.48%. Given Masimo Corporation’s higher probable upside, analysts clearly believe Masimo Corporation is more favorable than Tactile Systems Technology.
Institutional and Insider Ownership
84.1% of Masimo Corporation shares are held by institutional investors. Comparatively, 35.1% of Tactile Systems Technology shares are held by institutional investors. 16.6% of Masimo Corporation shares are held by company insiders. Comparatively, 49.9% of Tactile Systems Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Masimo Corporation beats Tactile Systems Technology on 8 of the 12 factors compared between the two stocks.
Masimo Corporation Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include non-invasive monitoring of blood constituents with an optical signature, optical organ oximetry monitoring, electrical, brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor, and the Radius-7 wearable wireless patient monitor. It offers Patient SafetyNet remote patient surveillance monitoring system, which allows patients to be monitored through a personal computer-based monitor or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.
Tactile Systems Technology Company Profile
Tactile Systems Technology, Inc. is a medical technology company that develops and provides medical devices for the treatment of chronic diseases at home. The Company is a manufacturer and distributor of the Flexitouch and Entre Systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition that is often an unintended consequence of cancer treatment, and the ACTitouch System, a medical device used to treat venous leg ulcers and chronic venous insufficiency. Its products deliver long-term treatment of chronic diseases. The Company provides its products for use in the home and sells them through vascular, wound and lymphedema clinics throughout the United States. The Company offers a platform to deliver at-home healthcare solutions throughout the United States. Its initial area of therapeutic focus is vascular disease, with a focus on advancing the care in treating lymphedema and chronic venous insufficiency.
What are top analysts saying about Masimo Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Masimo Corporation and related companies.